Jefferies Maintains a 'Buy' on Amarin (AMRN); Concern Over NCE Delay And Meta-analysis Presents A Buying Opportunity

September 12, 2012 7:08 AM EDT
Get Alerts AMRN Hot Sheet
Price: $2.90 -1.69%

Rating Summary:
    8 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade AMRN Now!
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $28.00.

Analyst, Thomas Wei, said, "We believe investor speculation over further delays in Vascepa’s New Chemical Entity (NCE) decision, plus a minor concern for a new meta-analysis, has contributed to stock weakness. We believe the stock reaction creates an attractive entry point, as we do not believe NCE status is essential for a pharma deal given the patent prospects or that the analysis of 1-2 gram Lovaza studies predicts the outcome of Vascepa’s REDUCE-IT trial."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $13.56 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment